These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 16569872)

  • 21. Structural Basis of Why Nelfinavir-Resistant D30N Mutant of HIV-1 Protease Remains Susceptible to Saquinavir.
    Prashar V; Bihani SC; Ferrer JL; Hosur MV
    Chem Biol Drug Des; 2015 Sep; 86(3):302-8. PubMed ID: 25487655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hydrophobic sliding: a possible mechanism for drug resistance in human immunodeficiency virus type 1 protease.
    Foulkes-Murzycki JE; Scott WR; Schiffer CA
    Structure; 2007 Feb; 15(2):225-33. PubMed ID: 17292840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. On the role of the R configuration of the reaction-intermediate isostere in HIV-1 protease-inhibitor binding: X-ray structure at 2.0 A resolution.
    Dusková J; Dohnálek J; Skálová T; Petroková H; Vondrácková E; Hradílek M; Konvalinka J; Soucek M; Brynda J; Fábry M; Sedlácek J; Hasek J
    Acta Crystallogr D Biol Crystallogr; 2006 May; 62(Pt 5):489-97. PubMed ID: 16627941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance.
    Hong L; Zhang XC; Hartsuck JA; Tang J
    Protein Sci; 2000 Oct; 9(10):1898-904. PubMed ID: 11106162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. X-ray crystallographic structure of ABT-378 (lopinavir) bound to HIV-1 protease.
    Stoll V; Qin W; Stewart KD; Jakob C; Park C; Walter K; Simmer RL; Helfrich R; Bussiere D; Kao J; Kempf D; Sham HL; Norbeck DW
    Bioorg Med Chem; 2002 Aug; 10(8):2803-6. PubMed ID: 12057670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protein promiscuity: drug resistance and native functions--HIV-1 case.
    Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
    J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Using Hierarchical Virtual Screening To Combat Drug Resistance of the HIV-1 Protease.
    Li N; Ainsworth RI; Ding B; Hou T; Wang W
    J Chem Inf Model; 2015 Jul; 55(7):1400-12. PubMed ID: 25993532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains.
    Tie Y; Boross PI; Wang YF; Gaddis L; Hussain AK; Leshchenko S; Ghosh AK; Louis JM; Harrison RW; Weber IT
    J Mol Biol; 2004 Apr; 338(2):341-52. PubMed ID: 15066436
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular dynamics and free energy studies on the wild-type and mutated HIV-1 protease complexed with four approved drugs: mechanism of binding and drug resistance.
    Alcaro S; Artese A; Ceccherini-Silberstein F; Ortuso F; Perno CF; Sing T; Svicher V
    J Chem Inf Model; 2009 Jul; 49(7):1751-61. PubMed ID: 19537723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phenylnorstatine inhibitor binding to HIV-1 protease: geometry, protonation, and subsite-pocket interactions analyzed at atomic resolution.
    Brynda J; Rezacova P; Fabry M; Horejsi M; Stouracova R; Sedlacek J; Soucek M; Hradilek M; Lepsik M; Konvalinka J
    J Med Chem; 2004 Apr; 47(8):2030-6. PubMed ID: 15056001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
    Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezácová P; Brynda J; Pokorná J; Plesek J; Grüner B; Grantz Sasková K; Václavíková J; Král V; Konvalinka J
    J Med Chem; 2008 Aug; 51(15):4839-43. PubMed ID: 18598016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs.
    Perryman AL; Lin JH; McCammon JA
    Protein Sci; 2004 Apr; 13(4):1108-23. PubMed ID: 15044738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamics of preferential substrate recognition in HIV-1 protease: redefining the substrate envelope.
    Ozen A; Haliloğlu T; Schiffer CA
    J Mol Biol; 2011 Jul; 410(4):726-44. PubMed ID: 21762811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Computational simulations of HIV-1 proteases--multi-drug resistance due to nonactive site mutation L90M.
    Ode H; Neya S; Hata M; Sugiura W; Hoshino T
    J Am Chem Soc; 2006 Jun; 128(24):7887-95. PubMed ID: 16771502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular dynamic and free energy studies of primary resistance mutations in HIV-1 protease-ritonavir complexes.
    Aruksakunwong O; Wolschann P; Hannongbua S; Sompornpisut P
    J Chem Inf Model; 2006; 46(5):2085-92. PubMed ID: 16995739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predicting drug-resistant mutations of HIV protease.
    Ishikita H; Warshel A
    Angew Chem Int Ed Engl; 2008; 47(4):697-700. PubMed ID: 18058968
    [No Abstract]   [Full Text] [Related]  

  • 37. Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance.
    Nalam MN; Ali A; Reddy GS; Cao H; Anjum SG; Altman MD; Yilmaz NK; Tidor B; Rana TM; Schiffer CA
    Chem Biol; 2013 Sep; 20(9):1116-24. PubMed ID: 24012370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.
    Soares RO; Batista PR; Costa MG; Dardenne LE; Pascutti PG; Soares MA
    J Mol Graph Model; 2010 Sep; 29(2):137-47. PubMed ID: 20541446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutron crystallography used to identify targets to improve HIV-1 protease inhibitor.
    Hill R
    Future Med Chem; 2013 Oct; 5(15):1705. PubMed ID: 24144407
    [No Abstract]   [Full Text] [Related]  

  • 40. 2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects.
    Degoey DA; Grampovnik DJ; Flentge CA; Flosi WJ; Chen HJ; Yeung CM; Randolph JT; Klein LL; Dekhtyar T; Colletti L; Marsh KC; Stoll V; Mamo M; Morfitt DC; Nguyen B; Schmidt JM; Swanson SJ; Mo H; Kati WM; Molla A; Kempf DJ
    J Med Chem; 2009 Apr; 52(8):2571-86. PubMed ID: 19323562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.